BioSpace News Archive

Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR-driven cancers, announced today that long-term efficacy and safety results from its completed Phase 2 registrational AMPECT study of nab-sirolimus in malignant PEComa were published in the Journal of Clinical Oncology (JCO).

Biomea Fusion, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases, announced that on March 1, 2024, the compensation committee of Biomea’s board of directors granted two new employees non-qualified stock options to purchase an aggregate of 7,000 shares of the Company’s common stock.

LeMaitre Vascular, Inc. announced that management will be participating in four upcoming investor conferences in March.

Braxia Scientific Corp., a medical research company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, today announced the filing of its financial statements and management discussion and analysis for the three months and nine months ended December 31, 2023.

ImmunoScape, a biotechnology company focused on next-generation T Cell receptor -based immunotherapies, announced that members of its executive team will present at two upcoming conferences, BioCentury-BayHelix East-West Summit 2024 and The State of Precision Medicine 2024.

Cytokinetics, Incorporated announced that on February 29, 2024 it granted stock options to purchase an aggregate of 28,500 shares of common stock to three new employees, whose employment commenced in February 2024, as a material inducement to their employment.

ORIC Pharmaceuticals, Inc. announced that on March 1, 2024, ORIC granted a total of 3,600 non-qualified stock options and 600 restricted stock units to one new non-executive employee who began their employment with ORIC in February 2024.

Kura Oncology, Inc. announced that on March 1, 2024, the Compensation Committee of the Company’s Board of Directors granted inducement awards consisting of nonstatutory stock options to purchase 93,000 shares of common stock to two new employees under the Company’s 2023 Inducement Option Plan.

Taysha Gene Therapies, Inc. announced that, on March 1, 2024, the Compensation Committee of Taysha’s Board of Directors granted four new employees, in the aggregate, options to purchase 347,000 shares of the Company’s common stock in connection with their employment.

BioNxt Solutions Inc. is pleased to report that the comparative pharmacokinetic study for its oral dissolvable film based proprietary Cladribine product for the treatment of Multiple Sclerosis has been completed.